Intravenous immunoglobulin iherapy in autoimmune mucocutaneous blistering diseases: A review of the evidence for its efficacy and safety

American Journal of Clinical Dermatology

Volumn 11, Issue 5, 2010, Pages 315-326

  Gürcan, Hakan M ^a   Jeph, Sunil ^a   Ahmed, Razzaque A ^a  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIINFLAMMATORY AGENT; BETA4 INTEGRIN; BULLOUS PEMPHIGOID ANTIGEN 1; BULLOUS PEMPHIGOID ANTIGEN 2; CHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ANTIBODY TITER; AUTOIMMUNE SKIN DISEASE; BLISTER; BULLOUS PEMPHIGOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; INTERMETHOD COMPARISON; MONOTHERAPY; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; IMMUNOLOGY; MUCOSA; PATHOLOGY; PEMPHIGUS;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS; PEMPHIGUS;

EID: 77954798045     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11533290-000000000-00000     Document Type: Review

References (44)

1. [No authors listed]. Evidence-based medicine: a new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA 1992 Nov 4; 268 (17): 2420-2425.
2. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature: II. How to use an article about therapy or prevention. A: are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993 Dec 1; 270 (21): 2598-2601.
3. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature: II. How to use an article about therapy or prevention. B: what were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1994 Jan 5; 271 (1): 59-63.
4. Guyatt GH, Rennie D. Users' guides to the medical literature. JAMA 1993 Nov 3; 270 (17): 2096-2097.
5. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int Immunopharmacol 2006 Apr; 6 (4): 557-578.
6. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003 Aug; 139 (8): 1051-1059.
7. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006 Apr; 117 (4 Suppl.): S525-53
8. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J AmAcad Dermatol 2009 Apr; 60 (4): 595-603.
9. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999 May; 140 (5): 865-874.
10. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001 Nov; 45 (5): 679-690.
11. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002 Sep; 47 (3): 358-363.
12. Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002 Sep; 138 (9): 1158-1162. (Pubitemid 35025687)
13. Wetter DA, DavisMD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review ofMayo Clinic experience.Mayo Clin Proc 2005 Jan; 80 (1): 41-47.
14. Baum S, Scope A, Barzilai A, et al. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006 May; 20 (5): 548-552.
15. Mittmann N, Chan B, Knowles S, et al. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J Cutan Med Surg 2006 Sep-Oct; 10 (5): 222-227.
16. Bystryn JC, JiaoD. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006 Nov; 39 (7): 601-607.
17. Sami N, Bhol KC, Ahmed AR. Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, longterm follow-up and treatment responses. Clin Exp Immunol 2001 Sep; 125 (3): 492-498.
18. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002 Jan; 46 (1): 42-49. (Pubitemid 34073476)
19. Sami N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol 2002 Mar-Apr; 12 (2): 174-178. (Pubitemid 34194176)
20. Segura S, Iranzo P, Martínez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007 Jun; 56 (6): 960-967.
21. Mignogna MD, Leuci S, Fedele S, et al. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study. Am J Clin Dermatol 2008; 9 (5): 323-331.
22. Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008 Dec; 144 (12): 1621-1624.
23. Asarch A, Razzaque Ahmed A. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy. Pediatr Dermatol 2009Mar-Apr; 26 (2): 197-202.
24. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999 Nov; 106 (11): 2136-2143.
25. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002 Jan; 102 (1): 59-67.
26. Ahmed AR, Colón JG. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001 Sep; 137 (9): 1181-1189.
27. Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004 Jun; 111 (3): 303-310.
28. SamiN, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy: long-term follow-up. Influence of treatment on antibody titres to human alpha6 integrin. Clin Exp Immunol 2002 Sep; 129 (3): 533-540.
29. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001 Dec; 45 (6): 825-835.
30. Mignogna MD, Leuci S, Piscopo R, et al. Intravenous immunoglobulins and mucous membrane pemphigoid. Ophthalmology 2008 Apr; 115 (4): 752-752.e1
31. Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 2002 Nov; 105 (2): 192-198.
32. Herzog S, Schmidt E, Goebeler M, et al. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84 (1): 48-52.
33. Letko E, Bhol K, Foster SC, et al. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid: a correlation with disease activity.Apreliminary study. Curr Eye Res 2000 Aug; 21 (2): 646-654.
34. Sami N, Ali S, Bhol KC, et al. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Agl and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003 Nov; 17 (6): 641-645.
35. Family Practice notebook.com. U.S. Preventive Services Task Force recommendations [online]. Available from URL: http://www.fpnotebook.com/ Prevent/Epi/UsPrvntvSrvcsTskFrcRcmndtns.htm [Accessed 2010 Jun 22]
36. CEBM. Oxford Centre for Evidence-based Medicine: levels of evidence (March 2009) [online]. Available from URL: http://www.cebm.net/index.aspx?o=1025 [Accessed 2010 Jun 22].
37. Gürcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 2007 Oct; 41 (10): 1604-1610.
38. Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004 Jul; 111 (7): 1380-1382.
39. Yeh SW,Usman AQ, AhmedAR. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol 2004 Sep; 112 (3): 268-272.
40. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005 Dec; 115 (l2): 3440-3450.
41. Mimouni D, Blank M, Ashkenazi L, et al. Protective effect of intravenous immunoglobulin (IVIg) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 2005 Dec; 142 (3): 426-432.
42. Arredondo J, Chernyavskv AI, Karaouni A, et al. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 2005 Dec; 167 (6): 1531-1544.
43. Waldman MH. Evidence-based medicine: how to translate research into patient care. J Am Podiatr Med Assoc 2006 Jul-Aug; 96 (4): 374-377.
44. Kesteloot H. Evidence-based medicine. Acta Cardiol 2006 Jun; 61 (3): 261-262.